TACSTD2 and neoplasm: In previous studies, administration of lysosomally-targeted (DeVay et al., 2017) anti-Trop-2 mAb in NHP toxicity studies resulted in target-mediated effects in skin and oral mucosa, consistent with Trop-2 on-target/off-tumor toxicity in these epithelial tissues.